Resumen de acción ICLR
ICON Public Limited Company, una organización de investigación clínica, presta servicios externalizados de desarrollo y comercialización en Irlanda, el resto de Europa, Estados Unidos y a escala internacional.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 5/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Recompensas
Análisis de riesgos
No se han detectado riesgos en ICLR a partir de nuestros controles de riesgos.
Competidores de ICON Public Limited Company
Historial de precios y rendimiento
| Historical stock prices | |
|---|---|
| Current Share Price | US$304.14 |
| 52 Week High | US$344.77 |
| 52 Week Low | US$181.92 |
| Beta | 1.16 |
| 1 Month Change | -9.47% |
| 3 Month Change | 15.85% |
| 1 Year Change | 55.61% |
| 3 Year Change | 42.46% |
| 5 Year Change | 115.29% |
| Change since IPO | 4,682.45% |
Noticias y actualizaciones recientes
ICON Public Limited Company Just Recorded A 8.9% EPS Beat: Here's What Analysts Are Forecasting Next
Apr 28
What Does ICON Public Limited Company's (NASDAQ:ICLR) Share Price Indicate?
Apr 21ICON Public Limited Company's (NASDAQ:ICLR) Intrinsic Value Is Potentially 33% Above Its Share Price
Apr 05Recent updates
ICON Public Limited Company Just Recorded A 8.9% EPS Beat: Here's What Analysts Are Forecasting Next
Apr 28What Does ICON Public Limited Company's (NASDAQ:ICLR) Share Price Indicate?
Apr 21ICON Public Limited Company's (NASDAQ:ICLR) Intrinsic Value Is Potentially 33% Above Its Share Price
Apr 05ICON Public Limited Company (NASDAQ:ICLR) Looks Just Right With A 27% Price Jump
Mar 05With EPS Growth And More, ICON (NASDAQ:ICLR) Makes An Interesting Case
Feb 07ICON: Will The Huge Acquisition Of PRA Continue To Create Synergies?
Feb 01These 4 Measures Indicate That ICON (NASDAQ:ICLR) Is Using Debt Reasonably Well
Jan 23Is It Too Late To Consider Buying ICON Public Limited Company (NASDAQ:ICLR)?
Jan 08What You Can Learn From ICON Public Limited Company's (NASDAQ:ICLR) P/E
Dec 24A Look At The Fair Value Of ICON Public Limited Company (NASDAQ:ICLR)
Dec 09With EPS Growth And More, ICON (NASDAQ:ICLR) Makes An Interesting Case
Nov 08Why ICON Public Limited Company (NASDAQ:ICLR) Could Be Worth Watching
Oct 09Is ICON (NASDAQ:ICLR) Using Too Much Debt?
Sep 23Calculating The Fair Value Of ICON Public Limited Company (NASDAQ:ICLR)
Sep 05Does ICON (NASDAQ:ICLR) Deserve A Spot On Your Watchlist?
Aug 03Is It Too Late To Consider Buying ICON Public Limited Company (NASDAQ:ICLR)?
Jun 30Is ICON (NASDAQ:ICLR) Using Too Much Debt?
Jun 12Calculating The Fair Value Of ICON Public Limited Company (NASDAQ:ICLR)
May 23Should You Think About Buying ICON Public Limited Company (NASDAQ:ICLR) Now?
Mar 29Is ICON (NASDAQ:ICLR) Using Too Much Debt?
Mar 11Are Investors Undervaluing ICON Public Limited Company (NASDAQ:ICLR) By 28%?
Feb 21Why ICON Public Limited Company (NASDAQ:ICLR) Could Be Worth Watching
Dec 28These 4 Measures Indicate That ICON (NASDAQ:ICLR) Is Using Debt Reasonably Well
Dec 10Is ICON Public Limited Company (NASDAQ:ICLR) Trading At A 26% Discount?
Nov 22Icon selected by BARDA to conduct anthrax vaccine clinical trial
Oct 06Is ICON Public Limited Company (NASDAQ:ICLR) Potentially Undervalued?
Sep 15ICON (NASDAQ:ICLR) Seems To Use Debt Quite Sensibly
Aug 26Baron Funds - ICON Plc: Positioned For An Extended Period Of Revenue And Earnings Growth
Aug 11Are Investors Undervaluing ICON Public Limited Company (NASDAQ:ICLR) By 41%?
Aug 01Icon Q2 2022 Earnings Preview
Jul 26ICON (NASDAQ:ICLR) Has A Pretty Healthy Balance Sheet
May 11ICON Public Limited Company (NASDAQ:ICLR) Shares Could Be 30% Below Their Intrinsic Value Estimate
Apr 20Is There Now An Opportunity In ICON Public Limited Company (NASDAQ:ICLR)?
Feb 16We Think ICON (NASDAQ:ICLR) Can Stay On Top Of Its Debt
Jan 26Estimating The Intrinsic Value Of ICON Public Limited Company (NASDAQ:ICLR)
Jan 05Is There Now An Opportunity In ICON Public Limited Company (NASDAQ:ICLR)?
Oct 31ICON (NASDAQ:ICLR) Has A Rock Solid Balance Sheet
Oct 16Estimating The Fair Value Of ICON Public Limited Company (NASDAQ:ICLR)
Oct 01ICON PLC: An Easy Stock To Choose For Diversified Exposure To Healthcare And Clinical Research
Aug 26Rentabilidad de los accionistas
| ICLR | US Life Sciences | Mercado US | |
|---|---|---|---|
| 7D | 2.1% | 3.2% | 2.0% |
| 1Y | 55.6% | 1.0% | 22.3% |
Rentabilidad vs. Industria: ICLR superó al sector US Life Sciences , que obtuvo un rendimiento del 1% el año pasado.
Rentabilidad vs. Mercado: ICLR superó al mercado US, que obtuvo un rendimiento del 24.9% el año pasado.
Volatilidad de los precios
| ICLR volatility | |
|---|---|
| ICLR Average Weekly Movement | 4.6% |
| Life Sciences Industry Average Movement | 6.9% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Precio estable de las acciones: ICLR no ha tenido una volatilidad de precios significativa en los últimos 3 meses.
Volatilidad a lo largo del tiempo: La volatilidad semanal de ICLR (5%) se ha mantenido estable durante el año pasado.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 1990 | 41,150 | Steve Cutler | www.iconplc.com |
ICON Public Limited Company, una organización de investigación clínica, presta servicios externalizados de desarrollo y comercialización en Irlanda, el resto de Europa, Estados Unidos y a escala internacional. La empresa está especializada en el desarrollo estratégico, la gestión y el análisis de programas que apoyan las distintas fases del proceso de desarrollo clínico, desde la selección de compuestos hasta los estudios clínicos de fase I-IV. También ofrece servicios de desarrollo clínico, que incluyen todas las fases de desarrollo, peri y post aprobación, soluciones de datos y servicios de acceso a centros y pacientes; servicios de gestión de ensayos clínicos, consultoría y contratación de personal; y servicios comerciales que comprenden la estrategia de desarrollo clínico, la planificación y el diseño de ensayos, la ejecución completa de estudios y la comercialización post comercialización.
Resumen de fundamentos de ICON Public Limited Company
| Estadísticas fundamentales de ICLR | |
|---|---|
| Capitalización bursátil | US$25.49b |
| Beneficios(TTM) | US$683.12m |
| Ingresos (TTM) | US$8.23b |
36.8x
Ratio precio-beneficio (PE)3.1x
Ratio precio-ventas (PS)¿Está ICLR sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de ICLR | |
|---|---|
| Ingresos | US$8.23b |
| Coste de los ingresos | US$5.79b |
| Beneficio bruto | US$2.44b |
| Otros gastos | US$1.76b |
| Beneficios | US$683.12m |
Últimos beneficios comunicados
Mar 31, 2024
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | 8.26 |
| Margen bruto | 29.69% |
| Margen de beneficio neto | 8.30% |
| Ratio deuda/patrimonio | 37.1% |
¿Cómo se ha desempeñado ICLR a largo plazo?
Ver rendimiento histórico y comparativa